C12N 2710/22011
Polyomaviridae
Official title: Polyomaviridae, e.g. polyoma, SV40, JC
C12N2710/22011 (Polyomaviridae) appears on 164 US grants and 231 published applications in this corpus.
Search patents in C12N- Granted patents
- 164
- Published applications
- 231
- Assignees
- 155
- Inventors
- 465
- Latest grant
- 28 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 3 | 0 |
| 1996 | 4 | 0 |
| 1997 | 7 | 0 |
| 1998 | 4 | 0 |
| 1999 | 10 | 0 |
| 2000 | 6 | 0 |
| 2001 | 4 | 1 |
| 2002 | 6 | 11 |
| 2003 | 2 | 9 |
| 2004 | 4 | 15 |
| 2005 | 0 | 9 |
| 2006 | 5 | 6 |
| 2007 | 2 | 8 |
| 2008 | 3 | 7 |
| 2009 | 7 | 11 |
| 2010 | 7 | 4 |
| 2011 | 5 | 9 |
| 2012 | 4 | 7 |
| 2013 | 3 | 3 |
| 2014 | 6 | 18 |
| 2015 | 4 | 7 |
| 2016 | 1 | 12 |
| 2017 | 12 | 8 |
| 2018 | 10 | 12 |
| 2019 | 8 | 12 |
| 2020 | 5 | 11 |
| 2021 | 5 | 9 |
| 2022 | 6 | 7 |
| 2023 | 4 | 13 |
| 2024 | 3 | 4 |
| 2025 | 6 | 11 |
| 2026 | 2 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2710/22022New viral proteins or individual genes, new structural or functional aspects ofIndexing code97
- C12N 2710/22041Use of virus, viral particle or viral elements as a vectorIndexing code45
- C12N 2710/22023Virus like particles [vlp]Indexing code31
- C12N 2710/22034Use of virus or viral component as vaccineIndexing code20
- C12N 2710/22061Methods of inactivation or attenuationIndexing code11
- C12N 2710/22051Methods of production or purification of viral materialIndexing code5
- C12N 2710/22032Use of virus as therapeutic agent, other than vaccineIndexing code4
- C12N 2710/22071Demonstrated in vivo effectIndexing code4
Recent patents
- Vaccine for preventing and treating Merkel cell carcinoma28 Jul 2026US 12,691,168 B2Advaccine (Suzhou) Biopharmaceuticals Co. Ltd.
- Composition for regulating production of interfering ribonucleic acid24 Mar 2026US 12,584,129 B1Wyvern Pharmaceuticals Inc.
- Composition for regulating production of interfering ribonucleic acid23 Dec 2025US 12,503,697 B1Wyvern Pharmaceuticals Inc.
- Composition for regulating production of interfering ribonucleic acid2 Dec 2025US 12,486,506 B1Wyvern Pharmaceuticals Inc.
- Composition for regulating production of interfering ribonucleic acid25 Nov 2025US 12,480,121 B1Wyvern Pharmaceuticals Inc.
- Treating a type i interferon upregulation or aberrant il-33 upregulation disease or condition with polyomavirus8 Oct 2026US 2026/0306609 A1The General Hospital Corporation
- Method for production of virus-like particles for gene delivery27 Aug 2026US 2026/0250644 A1Carnegie Mellon University
- Composition and method for the production of polyomaviral vector particles13 Aug 2026US 2026/0234658 A1Amarna Holding B.V.
- Method of assessing risk of pml16 Jul 2026US 2026/0202418 A1Biogen MA Inc.
- Composition for regulating production of interfering ribonucleic acid26 Mar 2026US 2026/0085312 A1Wyvern Pharmaceuticals Inc.
Most cited
By later US patents
- Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes185US 5,316,931 ABiosource Genetics Corporation · 1994
- Self-assembling polynucleotide delivery system comprising dendrimer polycations110US 5,661,025 A1997
- Recombinant plant viral nucleic acids105US 5,589,367 ABiosource Technologies, Inc. · 1996
- Transgenic animal model system for human cutaneous melanoma104US 5,550,316 AFox Chase Cancer Center · 1996
- Recombinant plant viral nucleic acids86US 5,866,785 ABiosource Technologies, Inc. · 1999